Yair Molad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yair Molad has a total of 139 co-authors. Here are the top co-authors by number of shared publications:
Jaqueline Sulkes
5 shared publicationsElisheva Pokroy-Shapira
Lupus Clinic, Rheumatology Unit, Beilinson Hospital, Rabin Medical Center, Beilinson Campus, Petach Tikva, 49100, Israel
3 shared publicationsKonstantine Bloch
3 shared publicationsVitaly Kliminski
Laboratory for Research of Inflammation Felsenstein Medical Research Center, Gray's Faculty of Medical and Health Sciences, Tel Aviv University Tel Aviv Israel
3 shared publicationsA Weinberger
2 shared publicationsAmir Fridenberg
2 shared publications
Latest Publications
- Open Access
- 25 January 2026
- Published by Wiley in Immunology
- Vol. 178 (2) , 249-260
TREM ‐1 Blockade Inhibits Inflammasome Activation and Pyroptosis: Novel Insights on the Role of TREM ‐1 and Syk in Monosodium Urate Crystal‐Induced Inflammation
Gout is associated with the upregulation of triggering receptor expressed on myeloid cells‐1 (TREM‐1) and soluble TREM‐1 (sTREM‐1). Cell activation signalling induced by monosodium urate (MSU) crystals and TREM‐1 signalling both converge on spleen tyrosine kinase (Syk). The aim of this study was to decipher the role of the TREM‐1 peptidomimetic inhibitor LP17, as well as Syk inhibitor, and their interaction during MSU‐induced cell inflammation, focusing on NLRP3 inflammasome activation, IL‐1β production and pyroptosis. In MSU‐activated cells, both LP17 and Syk inhibitor (iSyk) significantly reduced the secretion of IL‐1β and the release and activity of caspase‐1. LP17 changed the phosphorylation of Syk, indicating that inhibition of TREM‐1 modulates the activation state of Syk. Both LP17 and iSyk reduced the level of NLRP3‐induced apoptosis‐associated speck‐like protein (ASC) transcripts and MSU‐induced immunolabelling of ASC. Under confocal immunomicroscopy, TREM‐1 in MSU‐crystal‐activated cells was localised to the same perimembranal compartment with NLRP3 inflammasome; inhibition of TREM‐1 hindered the colocalisation of Syk with ASC. These results were corroborated by use of the in vitro ASC oligomerszation assay that showed that blocking TREM‐1 induced Syk redistribution from ASC complexes, indicating that LP17 can repress the ability of Syk to incorporate into the forming ASC speckle. Additionally, unlike iSyk, LP17 hampered MSU‐induced cleavage of gasdermin D, the hallmark of pyroptosis. Together, our findings suggest that blocking TREM‐1 may prove beneficial as a novel strategy in the treatment of gout as well as other inflammasome‐mediated diseases.
- 25 January 2026
- Published by Wiley in Immunology
- Vol. 178 (2) , 249-260
Open AccessTREM ‐1 Blockade Inhibits Inflammasome Activation and Pyroptosis: Novel Insights on the Role of TREM ‐1 and Syk in Monosodium Urate Crystal‐Induced Inflammation
Gout is associated with the upregulation of triggering receptor expressed on myeloid cells‐1 (TREM‐1) and soluble TREM‐1 (sTREM‐1). Cell activation signalling induced by monosodium urate (MSU) crystals and TREM‐1 signalling both converge on spleen tyrosine kinase (Syk). The aim of this study was to decipher the role of the TREM‐1 peptidomimetic inhibitor LP17, as well as Syk inhibitor, and their interaction during MSU‐induced cell inflammation, focusing on NLRP3 inflammasome activation, IL‐1β production and pyroptosis. In MSU‐activated cells, both LP17 and Syk inhibitor (iSyk) significantly reduced the secretion of IL‐1β and the release and activity of caspase‐1. LP17 changed the phosphorylation of Syk, indicating that inhibition of TREM‐1 modulates the activation state of Syk. Both LP17 and iSyk reduced the level of NLRP3‐induced apoptosis‐associated speck‐like protein (ASC) transcripts and MSU‐induced immunolabelling of ASC. Under confocal immunomicroscopy, TREM‐1 in MSU‐crystal‐activated cells was localised to the same perimembranal compartment with NLRP3 inflammasome; inhibition of TREM‐1 hindered the colocalisation of Syk with ASC. These results were corroborated by use of the in vitro ASC oligomerszation assay that showed that blocking TREM‐1 induced Syk redistribution from ASC complexes, indicating that LP17 can repress the ability of Syk to incorporate into the forming ASC speckle. Additionally, unlike iSyk, LP17 hampered MSU‐induced cleavage of gasdermin D, the hallmark of pyroptosis. Together, our findings suggest that blocking TREM‐1 may prove beneficial as a novel strategy in the treatment of gout as well as other inflammasome‐mediated diseases.
- Open Access
- 14 February 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (6) , 983-996
Second Trimester Kidney Function and Adverse Pregnancy Outcomes among Patients with Lupus
Key Points: In our combined cohort, second trimester kidney function was associated with adverse outcomes for patients with lupus. Measurement of kidney function during pregnancy may have potential benefit, especially among patients without kidney disease. Background: Kidney function is not routinely assessed during pregnancy. Several studies have proposed antepartum kidney function, particularly second trimester kidney function, as a potential predictor of adverse pregnancy outcomes. It has been previously established that patients with systemic lupus erythematosus are at increased risk for adverse pregnancy outcomes. The association between second trimester kidney function and adverse pregnancy outcomes has not been evaluated in diverse patient populations, particularly among patients with high obstetrical risk. Methods: In this observational study of pregnant patients with lupus in North America and Europe from 1995 to 2017, we used second trimester creatinine and eGFR to model the log odds of preeclampsia, preterm birth, low birthweight, fetal loss, and a composite of those outcomes. We incorporated these measures into a regression setting using fractional polynomials, and we further examined discrete formulations of eGFR. Results: Among 684 pregnancies in patients with lupus, the mean second trimester creatinine was 0.63 mg/dl ±SD 0.26 and the median value 0.60 (interquartile range, 0.50–0.70). At least 1 in 3 patients in this combined cohort experienced an adverse outcome. Mixtures of U-shaped and linear relationships between continuous kidney function and the log odds of adverse pregnancy outcomes were observed. Stratifying the cohort by diagnosis of lupus nephritis (LN; active or in remission) or without diagnosis of nephritis, we found differences in the relationship between kidney function and adverse outcomes. Conclusions: We observed high rates of adverse pregnancy outcomes in our diverse patient population comprised of pregnant patients with lupus with and without LN. We identified complex relationships between second trimester kidney function and adverse pregnancy outcomes that differed by the outcome and diagnosis of LN.
- 14 February 2025
- Published by Wolters Kluwer Health in Kidney360
- Vol. 6 (6) , 983-996
Open AccessSecond Trimester Kidney Function and Adverse Pregnancy Outcomes among Patients with Lupus
Key Points: In our combined cohort, second trimester kidney function was associated with adverse outcomes for patients with lupus. Measurement of kidney function during pregnancy may have potential benefit, especially among patients without kidney disease. Background: Kidney function is not routinely assessed during pregnancy. Several studies have proposed antepartum kidney function, particularly second trimester kidney function, as a potential predictor of adverse pregnancy outcomes. It has been previously established that patients with systemic lupus erythematosus are at increased risk for adverse pregnancy outcomes. The association between second trimester kidney function and adverse pregnancy outcomes has not been evaluated in diverse patient populations, particularly among patients with high obstetrical risk. Methods: In this observational study of pregnant patients with lupus in North America and Europe from 1995 to 2017, we used second trimester creatinine and eGFR to model the log odds of preeclampsia, preterm birth, low birthweight, fetal loss, and a composite of those outcomes. We incorporated these measures into a regression setting using fractional polynomials, and we further examined discrete formulations of eGFR. Results: Among 684 pregnancies in patients with lupus, the mean second trimester creatinine was 0.63 mg/dl ±SD 0.26 and the median value 0.60 (interquartile range, 0.50–0.70). At least 1 in 3 patients in this combined cohort experienced an adverse outcome. Mixtures of U-shaped and linear relationships between continuous kidney function and the log odds of adverse pregnancy outcomes were observed. Stratifying the cohort by diagnosis of lupus nephritis (LN; active or in remission) or without diagnosis of nephritis, we found differences in the relationship between kidney function and adverse outcomes. Conclusions: We observed high rates of adverse pregnancy outcomes in our diverse patient population comprised of pregnant patients with lupus with and without LN. We identified complex relationships between second trimester kidney function and adverse pregnancy outcomes that differed by the outcome and diagnosis of LN.
- 9 October 2024
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Soluble TREM-1 ameliorates gouty arthritis by selective inhibition of proinflammatory cytokines and chemokines without affecting TGFβ production.
Full Papers; Authors: Y. Molad, I. Lagovsky
- 9 October 2024
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
Soluble TREM-1 ameliorates gouty arthritis by selective inhibition of proinflammatory cytokines and chemokines without affecting TGFβ production.
Full Papers; Authors: Y. Molad, I. Lagovsky
- Open Access
- 26 August 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (34) , e30152
Diagnostic utility of clinical characteristics, laboratory tests, and serum ferritin in diagnosis of adult-onset Still disease
The diagnosis of adult-onset Still disease (AOSD) is challenging with ambiguous clinical presentation and no specific serological markers. We aim to evaluate the diagnostic utility of clinical, laboratory and serum ferritin features in established AOSD patients. We included all patients >18 years who were admitted to 2 tertiary medical centers (2003–2019) with serum ferritin above 1000 ng/mL. AOSD patients and non-AOSD controls were matched in 1:4 ratio for age and sex. The primary outcomes were sensitivity, specificity, positive/negative likelihood ratio and area under the curve (AUC) using clinical and laboratory characteristics based on the Yamaguchi classification criteria, in addition to serum ferritin. We identified 2658 patients with serum ferritin above 1000 ng/m, of whom 36 diagnosed with AOSD and 144 non-AOSD matched controls. Presence of arthralgia/arthritis showed the highest sensitivity (0.74), specificity (0.93), positive likelihood ratio (10.69), negative likelihood ratio (0.27) and AUC (0.83, 95% confidence interval 0.74–0.92) to the diagnosis of AOSD. On the other hand, serum ferritin showed variation and poorer results, depends on the chosen ferritin cutoff. Joint involvement showed the best diagnostic utility to establish the diagnosis of AOSD. Although clinicians use often elevated ferritin levels as an anchor to AOSD, the final diagnosis should be based on thorough clinical evaluation.
- 26 August 2022
- Published by Wolters Kluwer Health in Medicine
- Vol. 101 (34) , e30152
Open AccessDiagnostic utility of clinical characteristics, laboratory tests, and serum ferritin in diagnosis of adult-onset Still disease
The diagnosis of adult-onset Still disease (AOSD) is challenging with ambiguous clinical presentation and no specific serological markers. We aim to evaluate the diagnostic utility of clinical, laboratory and serum ferritin features in established AOSD patients. We included all patients >18 years who were admitted to 2 tertiary medical centers (2003–2019) with serum ferritin above 1000 ng/mL. AOSD patients and non-AOSD controls were matched in 1:4 ratio for age and sex. The primary outcomes were sensitivity, specificity, positive/negative likelihood ratio and area under the curve (AUC) using clinical and laboratory characteristics based on the Yamaguchi classification criteria, in addition to serum ferritin. We identified 2658 patients with serum ferritin above 1000 ng/m, of whom 36 diagnosed with AOSD and 144 non-AOSD matched controls. Presence of arthralgia/arthritis showed the highest sensitivity (0.74), specificity (0.93), positive likelihood ratio (10.69), negative likelihood ratio (0.27) and AUC (0.83, 95% confidence interval 0.74–0.92) to the diagnosis of AOSD. On the other hand, serum ferritin showed variation and poorer results, depends on the chosen ferritin cutoff. Joint involvement showed the best diagnostic utility to establish the diagnosis of AOSD. Although clinicians use often elevated ferritin levels as an anchor to AOSD, the final diagnosis should be based on thorough clinical evaluation.
- 10 April 2022
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 41 (5) , 1155-1162
Urine soluble triggering receptor expressed on myeloid cells-1 is a novel biomarker for active lupus nephritis: a case-control study
Full Papers; Authors: Y. Molad, M. Egbaria, A. Tovar, A. Dortort Lazar, E. Pokroy Shapira, S. Oren, Y. Edel, V. Kliminski
- 10 April 2022
- Published by Clinical and Experimental Rheumatology in Clinical and Experimental Rheumatology
- Vol. 41 (5) , 1155-1162
Urine soluble triggering receptor expressed on myeloid cells-1 is a novel biomarker for active lupus nephritis: a case-control study
Full Papers; Authors: Y. Molad, M. Egbaria, A. Tovar, A. Dortort Lazar, E. Pokroy Shapira, S. Oren, Y. Edel, V. Kliminski
- 27 November 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (3) , 921-928
Diffused coronary involvement in Takayasu arteritis with concomitant malignancy
Large vessel vasculitis (LVV) is composed of conditions in which inflammation of blood vessel walls affects mainly large arteries, such as the aorta and its main branches, and in some cases the coronary arteries. Coronary artery involvement in systemic vasculitis is associated with significant morbidity and mortality. We present a case of a young patient diagnosed with extensive coronary disease diagnosed as Takayasu arteritis, when whom a concomitant diagnosis of Hodgkin’s lymphoma was made. The literature review revealed ten cases of malignancies associated with Takayasu arteritis. We discuss the complexity of the management of concurrent hematological malignancy with TAK and extensive coronary arteritis. This complicated and cross-disciplinary case also represents the pivotal importance of multi-disciplinary team decision in order to achieve the best clinical outcome of both disorders.
- 27 November 2021
- Published by Springer Nature in Clinical Rheumatology
- Vol. 41 (3) , 921-928
Diffused coronary involvement in Takayasu arteritis with concomitant malignancy
Large vessel vasculitis (LVV) is composed of conditions in which inflammation of blood vessel walls affects mainly large arteries, such as the aorta and its main branches, and in some cases the coronary arteries. Coronary artery involvement in systemic vasculitis is associated with significant morbidity and mortality. We present a case of a young patient diagnosed with extensive coronary disease diagnosed as Takayasu arteritis, when whom a concomitant diagnosis of Hodgkin’s lymphoma was made. The literature review revealed ten cases of malignancies associated with Takayasu arteritis. We discuss the complexity of the management of concurrent hematological malignancy with TAK and extensive coronary arteritis. This complicated and cross-disciplinary case also represents the pivotal importance of multi-disciplinary team decision in order to achieve the best clinical outcome of both disorders.
- Open Access
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Elevated Plasma Soluble Triggering Receptor Expressed on Myeloid Cells‐1 Level in Patients with Acute Coronary Syndrome (ACS): A Biomarker of Disease Severity and Outcome
Background and Aims. Plasma levels of soluble triggering receptor expressed on myeloid cells (sTREM‐1) reflect innate immune cell activation. We sought to evaluate sTREM‐1 levels in patients with acute coronary syndrome (ACS) and their predictive value for disease severity and outcome. Methods. Plasma sTREM‐1 levels were prospectively measured by ELISA in 121 consecutive patients with new‐onset (≤24 h) chest pain at arrival to the emergency department (ED) and 73 healthy controls. Secondary endpoints were the association of plasma levels of sTREM‐1 with day 30 and month 6 major adverse cardiovascular events (MACE) defined as death, ACS, stroke, and need for coronary revascularization, as well as with CAD severity. The primary endpoint of the study was the association of plasma sTREM‐1 level at the time of admission to the ED with a diagnosis of ACS at day 30. Results. Fifty‐nine patients (48.7%) were diagnosed with ACS and 62 (51.3%) with nonspecific chest pain (NSCP). Median plasma sTREM‐1 level at admission was significantly higher in the ACS group than the NSCP group and the control group (539.4 ± 330.3 pg/ml vs. 432.5 ± 196.4 pg/ml vs. 230.1 ± 85.5 pg/ml, respectively; P < 0.001) and positively correlated with the number of stenosed/occluded coronary arteries on angiography (P < 0.001). On logistic regression analysis, higher sTREM‐1 levels predicted definite ACS vs. NSCP determined on day 30 (OR 1.29, 95% CI 1.07‐1.54, P = 0.01) as well as with recurrent ACS (P = 0.04) and stroke (P = 0.02) at 6 months. Conclusions. Plasma sTREM‐1 levels are significantly elevated in patients with ACS and might serve as a biomarker differentiating ACS from NSCP in the ED as well as an inflammatory biomarker for coronary artery disease severity and outcome.
- 1 January 2021
- Published by Wiley in Mediators of Inflammation
- Vol. 2021 (1)
Open AccessElevated Plasma Soluble Triggering Receptor Expressed on Myeloid Cells‐1 Level in Patients with Acute Coronary Syndrome (ACS): A Biomarker of Disease Severity and Outcome
Background and Aims. Plasma levels of soluble triggering receptor expressed on myeloid cells (sTREM‐1) reflect innate immune cell activation. We sought to evaluate sTREM‐1 levels in patients with acute coronary syndrome (ACS) and their predictive value for disease severity and outcome. Methods. Plasma sTREM‐1 levels were prospectively measured by ELISA in 121 consecutive patients with new‐onset (≤24 h) chest pain at arrival to the emergency department (ED) and 73 healthy controls. Secondary endpoints were the association of plasma levels of sTREM‐1 with day 30 and month 6 major adverse cardiovascular events (MACE) defined as death, ACS, stroke, and need for coronary revascularization, as well as with CAD severity. The primary endpoint of the study was the association of plasma sTREM‐1 level at the time of admission to the ED with a diagnosis of ACS at day 30. Results. Fifty‐nine patients (48.7%) were diagnosed with ACS and 62 (51.3%) with nonspecific chest pain (NSCP). Median plasma sTREM‐1 level at admission was significantly higher in the ACS group than the NSCP group and the control group (539.4 ± 330.3 pg/ml vs. 432.5 ± 196.4 pg/ml vs. 230.1 ± 85.5 pg/ml, respectively; P < 0.001) and positively correlated with the number of stenosed/occluded coronary arteries on angiography (P < 0.001). On logistic regression analysis, higher sTREM‐1 levels predicted definite ACS vs. NSCP determined on day 30 (OR 1.29, 95% CI 1.07‐1.54, P = 0.01) as well as with recurrent ACS (P = 0.04) and stroke (P = 0.02) at 6 months. Conclusions. Plasma sTREM‐1 levels are significantly elevated in patients with ACS and might serve as a biomarker differentiating ACS from NSCP in the ED as well as an inflammatory biomarker for coronary artery disease severity and outcome.
- Open Access
- 19 March 2019
- Published by Springer Nature in BMC Rheumatology
- Vol. 3 (1) , 11
Incident gout and chronic Kidney Disease: healthcare utilization and survival
Uncontrolled gout can cause significant joint and organ damage and has been associated with impairments in quality of life and high economic cost. Gout has also been associated with other comorbid diseases, such as chronic kidney disease. The current study explored if healthcare resource utilization (HRU) and survival differs between patients with incident gout in the presence or absence of chronic kidney disease (CKD). Clalit Health Services (CHS) data were used to conduct a retrospective population-based cohort study of incident gout between 1/1/2006-31/12/2009. Incident cases of gout were identified and stratified by CKD status and by age group (< 55 and 55+ years). CKD status was defined as a pre-existing diagnosis of chronic kidney disease, chronic renal failure, kidney transplantation, or dialysis at index date. Demographic and clinical characteristics, as well as healthcare resource use, were reported. A total of 12,940 incident adult gout patients, with (n = 8286) and without (n = 4654) CKD, were followed for 55,206 person-years. Higher rates of HRU were observed for gout patients with CKD than without. Total annual hospital admissions for patients with gout and CKD were at least 3 times higher for adults < 55 (mean = 0.51 vs 0.13) and approximately 1.5 times higher for adults 55+ (mean = 0.46 vs 0.29) without CKD. Healthcare utilization rates from year 1 to year 5 remained similar for gout patients < 55 years irrespective of CKD status, however varied according to healthcare utilization by CKD status for gout patients 55+ years. The 5-year all-cause mortality was higher among those with CKD compared to those without CKD for both age groups (HR< 55 years = 1.65; 95% CI 1.01-2.71; HR55+ years = 1.50; 95% CI 1.37-1.65). The current study suggests important differences exist in patient characteristics and outcomes among patients with gout and CKD. Healthcare utilization differed between sub-populations, age and comorbidities, over the study period and the 5-year mortality risk was higher for gout patients with CKD, regardless of age. Future work should explore factors associated with these outcomes and barriers to gout control in order to enhance patient management among this high-risk subgroup.
- 19 March 2019
- Published by Springer Nature in BMC Rheumatology
- Vol. 3 (1) , 11
Open AccessIncident gout and chronic Kidney Disease: healthcare utilization and survival
Uncontrolled gout can cause significant joint and organ damage and has been associated with impairments in quality of life and high economic cost. Gout has also been associated with other comorbid diseases, such as chronic kidney disease. The current study explored if healthcare resource utilization (HRU) and survival differs between patients with incident gout in the presence or absence of chronic kidney disease (CKD). Clalit Health Services (CHS) data were used to conduct a retrospective population-based cohort study of incident gout between 1/1/2006-31/12/2009. Incident cases of gout were identified and stratified by CKD status and by age group (< 55 and 55+ years). CKD status was defined as a pre-existing diagnosis of chronic kidney disease, chronic renal failure, kidney transplantation, or dialysis at index date. Demographic and clinical characteristics, as well as healthcare resource use, were reported. A total of 12,940 incident adult gout patients, with (n = 8286) and without (n = 4654) CKD, were followed for 55,206 person-years. Higher rates of HRU were observed for gout patients with CKD than without. Total annual hospital admissions for patients with gout and CKD were at least 3 times higher for adults < 55 (mean = 0.51 vs 0.13) and approximately 1.5 times higher for adults 55+ (mean = 0.46 vs 0.29) without CKD. Healthcare utilization rates from year 1 to year 5 remained similar for gout patients < 55 years irrespective of CKD status, however varied according to healthcare utilization by CKD status for gout patients 55+ years. The 5-year all-cause mortality was higher among those with CKD compared to those without CKD for both age groups (HR< 55 years = 1.65; 95% CI 1.01-2.71; HR55+ years = 1.50; 95% CI 1.37-1.65). The current study suggests important differences exist in patient characteristics and outcomes among patients with gout and CKD. Healthcare utilization differed between sub-populations, age and comorbidities, over the study period and the 5-year mortality risk was higher for gout patients with CKD, regardless of age. Future work should explore factors associated with these outcomes and barriers to gout control in order to enhance patient management among this high-risk subgroup.
- Open Access
- 7 January 2019
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 21 (1) , 10
Elevated plasma level of soluble triggering receptor expressed on myeloid cells-1 is associated with inflammation activity and is a potential biomarker of thrombosis in primary antiphospholipid syndrome
Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is an innate-immune receptor found in blood. Its presence reflects innate immune cell activation. We sought to investigate plasma sTREM-1 levels in patients with primary antiphospholipid syndrome (PAPS). A cross-sectional, case-control design was used. Plasma sTREM-1 levels were analyzed by enzyme-linked immunosorbent assay (ELISA) in consecutive patients diagnosed with PAPS or asymptomatic antiphospholipid antibody (APLA) carriers and controls. The study cohort included 33 patients with PAPS, 10 asymptomatic APLA carriers, and 73 controls. Mean plasma sTREM-1 levels were significantly higher in patients with PAPS (299.2 ± 146.7 pg/ml) and thrombotic PAPS-ever (current and past thrombotic event) (327.2 ± 151.3 pg/ml) compared with controls (230.2 ± 85.5 pg/ml; p = 0.006 and p = 0.003, respectively), patients with thrombotic PAPS compared with patients with past obstetric APS (195.12 ± 58.52 pg/ml, p = 0.01) and APLA carriers (215.8 ± 51.6 pg/ml, p = 0.02), patients with current thrombotic PAPS (429.5 ± 227.5 pg/ml) compared with patients with past thrombotic PAPS (289.5 ± 94.65 pg/ml, p = 0.01), and patients with PAPS who had ever had a stroke or venous thromboembolic event compared with patients who had not (p = 0.007 and p = 0.02, respectively). On receiver operator characteristic curve analysis, plasma sTREM-1 levels differentiated patients with current thrombotic PAPS from asymptomatic APLA carriers and controls, with an area under the curve of 0.7292 (p = 0.0014) and 0.88 (p < 0.0001), respectively. Multivariate regression analysis to identify sTREM-1 predictors (thrombotic PAPS-ever, age, and sex) yielded an independent association of sTREM-1 levels with thrombotic PAPS (p < 0.0001). Plasma sTREM-1 levels are significantly elevated in patients with thrombotic PAPS. Levels of sTREM-1 might serve as a biomarker for thrombosis in patients with PAPS.
- 7 January 2019
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 21 (1) , 10
Open AccessElevated plasma level of soluble triggering receptor expressed on myeloid cells-1 is associated with inflammation activity and is a potential biomarker of thrombosis in primary antiphospholipid syndrome
Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) is an innate-immune receptor found in blood. Its presence reflects innate immune cell activation. We sought to investigate plasma sTREM-1 levels in patients with primary antiphospholipid syndrome (PAPS). A cross-sectional, case-control design was used. Plasma sTREM-1 levels were analyzed by enzyme-linked immunosorbent assay (ELISA) in consecutive patients diagnosed with PAPS or asymptomatic antiphospholipid antibody (APLA) carriers and controls. The study cohort included 33 patients with PAPS, 10 asymptomatic APLA carriers, and 73 controls. Mean plasma sTREM-1 levels were significantly higher in patients with PAPS (299.2 ± 146.7 pg/ml) and thrombotic PAPS-ever (current and past thrombotic event) (327.2 ± 151.3 pg/ml) compared with controls (230.2 ± 85.5 pg/ml; p = 0.006 and p = 0.003, respectively), patients with thrombotic PAPS compared with patients with past obstetric APS (195.12 ± 58.52 pg/ml, p = 0.01) and APLA carriers (215.8 ± 51.6 pg/ml, p = 0.02), patients with current thrombotic PAPS (429.5 ± 227.5 pg/ml) compared with patients with past thrombotic PAPS (289.5 ± 94.65 pg/ml, p = 0.01), and patients with PAPS who had ever had a stroke or venous thromboembolic event compared with patients who had not (p = 0.007 and p = 0.02, respectively). On receiver operator characteristic curve analysis, plasma sTREM-1 levels differentiated patients with current thrombotic PAPS from asymptomatic APLA carriers and controls, with an area under the curve of 0.7292 (p = 0.0014) and 0.88 (p < 0.0001), respectively. Multivariate regression analysis to identify sTREM-1 predictors (thrombotic PAPS-ever, age, and sex) yielded an independent association of sTREM-1 levels with thrombotic PAPS (p < 0.0001). Plasma sTREM-1 levels are significantly elevated in patients with thrombotic PAPS. Levels of sTREM-1 might serve as a biomarker for thrombosis in patients with PAPS.
- 7 November 2017
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 47 (12)
Response to the letter to the editor by Gkougkourelas et al – EJCI‐2017‐0361
- 7 November 2017
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 47 (12)
Response to the letter to the editor by Gkougkourelas et al – EJCI‐2017‐0361